**Mari 2005**

1 Treatments

**Studied treatment** 30, 60, or 120 mg nateglinide

**Control treatment** placebo

**Concomittant treatments** -

2 Patients

**Patients** mild type 2 diabetic men and women (fasting glucose 7.0-8.3 mmol/l) on diet treatment

**Inclusion criteria** -

**Exclusion criteria** -

3 Methods

**Blinding** double-blind

**Design** Parallel groups

**Centers** -

**Geographical area** -

**Sizes** 108/0

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
</table>

5 References